AFMD Articles, Affimed N.V.

No one has written and article on Affimed N.V., stock symbol AFMD. Be the first to contribute and write an article.

Stock Information

Affimed N.V. Company Name:

AFMD Stock Symbol:

NASDAQ Market:

Get AFMD Alerts

News, Short Squeeze, Breakout and More Instantly...

AFMD - Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-nega...
AFMD - Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022 AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and ...
AFMD - Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumors Design and rationale of the phase 1/2a study of AFM24 in combination with atezolizumab in patients with advanced EGFR-expressing solid t...